Ipertrofan

Mepartricin, the active ingredient in Ipertrofan, is a macrolide antibiotic presented as an oral tablet for oral use. It treats chronic prostatitis and chronic pelvic pain syndrome in adult males.

GNH USA supplies Ipertrofan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mepartricin is used in the urological therapeutic area to manage chronic inflammatory conditions of the prostate.

- Chronic prostatitis: reduces prostatic inflammation and alleviates urinary symptoms. - Chronic pelvic pain syndrome: improves pelvic discomfort associated with prostatitis. - Prostatic infection: supports treatment of bacterial prostatitis by targeting pathogenic bacteria.

Adverse reactions may occur with Mepartricin therapy.

Common Side Effects: - Nausea - Abdominal discomfort - Diarrhea - Headache - Dizziness - Altered taste perception

Serious or Rare Side Effects: - Anaphylactic reaction - Elevated liver enzymes - Neutropenia - Severe skin reactions such as Stevens‑Johnson syndrome - Cardiac arrhythmias (QT prolongation) - Clostridioides difficile‑associated colitis

Before initiating Mepartricin, consider the following safety measures.

- Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: unknown; assess potential infant exposure. - Renal impairment: monitor renal function and adjust if necessary. - Hepatic impairment: periodic liver‑function tests are recommended. - Drug interactions: review concomitant medications for potential interactions. - Store at below 25°C: keep in the original pack, protect from moisture.

Mepartricin may interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - QT‑prolonging agents: increased risk of cardiac arrhythmia. - Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): may raise Mepartricin plasma levels. - Anticoagulants (warfarin): potential enhancement of anticoagulant effect. - Live vaccines: possible reduction in vaccine efficacy. - Teratogenic drugs: avoid concurrent use during pregnancy.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Diuretics: monitor electrolytes for imbalance. - NSAIDs: increased risk of gastrointestinal irritation. - Probenecid: may alter renal excretion of Mepartricin. - Oral contraceptives: monitor for possible reduced effectiveness.